Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Amylyx Pharmaceuticals' Avexitide Phase 3 Success: What Investors Need to Know

Amylyx's Phase 3 success with avexitide shows promise for investors, especially amid past setbacks.

Aug 18, 2026
Pharmaceutical

Analyzing the Fulcrum and Slate Merger: A New Era for Migraine Therapies

Fulcrum Therapeutics and Slate Medicines merge to create a powerhouse in migraine therapies, signaling a pivotal shift in the CNS market.

Aug 17, 2026
Pharmaceutical

Iovance Biotherapeutics' Q2 Earnings: Strong Momentum in Oncology

Iovance Biotherapeutics showcases promising developments in oncology, highlighted by a key FDA designation and strong clinical response rate…

Aug 16, 2026
Pharmaceutical

Moderna's mRNA Flu Vaccine Approval: A Game Changer for Investors

Moderna's FDA approval of the first mRNA flu vaccine could redefine its market potential and growth trajectory.

Aug 16, 2026
Pharmaceutical

Bristol Myers Squibb's FDA Approval: Is the Market Overreacting?

Bristol Myers Squibb's recent FDA approval raises questions about investor sentiment and stock valuation.

Aug 15, 2026
Pharmaceutical

BridgeBio Pharma Stock Gains 29%: Analyzing Wall Street's Confidence

BridgeBio Pharma's stock has surged 29% in three months, reflecting strong earnings and bullish analyst support.

Aug 14, 2026
Pharmaceutical

Lantheus Holdings' Tauklarify Approval: A Game Changer for Alzheimer's Imaging

Lantheus Holdings receives FDA approval for Tauklarify, enhancing its position in the Alzheimer's diagnostics market.

Aug 14, 2026
Pharmaceutical

Capricor Therapeutics' Stock Soars 77%: What It Means for Investors

Capricor Therapeutics shares surged 77% after FDA agreed to review DMD drug data, signaling a turnaround for the biotech.

Aug 14, 2026
Pharmaceutical

Capricor Therapeutics: A High-Stakes Bet on FDA Decision

Capricor Therapeutics' stock surged 67% after-hours amidst anticipation of an FDA decision on deramiocel.

Aug 14, 2026
Pharmaceutical

Outlook Therapeutics Faces Investor Backlash Post-FDA Approval: A Cautionary Tale

Outlook Therapeutics (OTLK) faces investor backlash as capital raise impacts share prices despite FDA approval of LYTENAVA.

Aug 13, 2026
Pharmaceutical

Cullinan Oncology's Path to FDA Approval: What Investors Need to Know

Cullinan Oncology's recent Phase 3 trial results signal a pivotal moment for investors as the company pursues FDA approval.

Aug 13, 2026
Pharmaceutical

Cullinan Oncology's Stock Surge: Analyzing the Impact of Phase 3 Trial Results

Cullinan Oncology's positive Phase 3 trial results could reshape its market position and attract significant investor interest.

Aug 13, 2026